Coronavirus
disease 19 (COVID-19) is the ongoing global health
emergency caused by SARS-CoV-2 infection. The virus is highly contagious,
affecting millions of people worldwide. SARS-CoV-2, with its trimeric
spike glycoprotein, interacts with the angiotensin-converting enzyme
2 (ACE2) receptor and other co-receptors like basigin to invade the
host cell. Moreover, certain host proteases like transmembrane serine
proteases, furin, neuropilin 1 (NRP1), and endosomal cathepsins are
involved in the priming of spike glycoproteins at the S1/S2 interface.
This is critical for the entry of viral genome and its replication
in the host cytoplasm. Vaccines and anti-SARS-CoV-2 drugs have been
developed to overcome the infection. Nonetheless, the frequent emergence
of mutant variants of the virus has imposed serious concerns regarding
the efficacy of therapeutic agents, including vaccines that were developed
for previous strains. Thus, screening and development of pharmaceutical
agents with multi-target potency could be a better choice to restrain
SARS-CoV-2 infection. Madecassic acid (MDCA) is a pentacyclic triterpenoid
found in Centella asiatica. It has
multiple medicinal properties like anti-oxidative, anti-inflammatory,
and anti-diabetic potential. However, its implication as an anti-
SARS-CoV-2 agent is still obscure. Hence, in the present in silico
study, the binding affinities of MDCA for spike proteins, their receptors,
and proteases were investigated. Results indicated that MDCA interacts
with ligand-binding pockets of the spike receptor binding domain,
ACE2, basigin, and host proteases, viz. transmembrane serine proteinase,
furin, NRP1, and endosomal cathepsins, with greater affinities. Moreover,
the MDCA–protein interface was strengthened by prominent hydrogen
bonds and several hydrophobic interactions. Therefore, MDCA could
be a promising multi-target therapeutic agent against SARS-CoV-2 infection.